Showing results (111-120 of 125) with videos related to
Sort By:
Pageof 13
Clinical and Translational Gastroenterology|July 8, 2024
Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B StudyCynthia Levy, Stephen Caldwell, Parvez Mantry, et al.Gastroenterology|August 7, 2012
Lymphotoxin β receptor signaling promotes development of autoimmune pancreatitisGitta M Seleznik, Theresia Reding, Franziska Romrig, et al.Journal of Hepatology|June 14, 2021
Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver diseaseCarolin Lackner, Rudolf E Stauber, Susan Davies, et al.Hepatology (Baltimore, Md.)|January 21, 2019
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing CholangitisMichael Trauner, Aliya Gulamhusein, Bilal Hameed, et al.Hepatology (Baltimore, Md.)|August 29, 2018
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the DiseaseAndrew J Muir, Cynthia Levy, Harry L A Janssen, et al.Hepatology (Baltimore, Md.)|April 18, 2019
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab TrialsArun J Sanyal, Stephen A Harrison, Vlad Ratziu, et al.Biochemical Pharmacology|May 26, 2007
Modulation of hepatic microsomal triglyceride transfer protein (MTP) induced by S-nitroso-N-acetylcysteine in ob/ob miceClaudia P M S Oliveira, Venâncio A F Alves, Vicência M R Lima, et al.Journal of Hepatology|November 28, 2024
Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver diseaseJuan Pablo Arab, Luis Antonio Díaz, Jürgen Rehm, et al.Gastroenterology|July 11, 2018
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic SteatohepatitisStephen A Harrison, Manal F Abdelmalek, Stephen Caldwell, et al.Journal for Immunotherapy of Cancer|October 6, 2025
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumabBernhard Scheiner, Pasquale Lombardi, Antonio D'Alessio, et al.Pageof 13